Effect of PD-L1 blockade on function of dendritic cells derived from chronic myelocytic leukemia.
- Author:
Chun-Yan WANG
1
;
Lian-Sheng ZHANG
;
Fa-Qing TIAN
;
Rui HUANG
Author Information
1. Department of Hematology and Oncology, The Second Hospital, Lanzhou University, Lanzhou, 730030, Gansu Province, China.
- Publication Type:Journal Article
- MeSH:
Antigens, CD;
metabolism;
B7-H1 Antigen;
Dendritic Cells;
cytology;
immunology;
metabolism;
Granulocyte-Macrophage Colony-Stimulating Factor;
pharmacology;
Humans;
Interferon-gamma;
metabolism;
Interleukin-10;
metabolism;
Interleukin-2;
metabolism;
Interleukin-4;
pharmacology;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
immunology;
metabolism;
Recombinant Proteins;
Tumor Necrosis Factor-alpha;
pharmacology
- From:
Journal of Experimental Hematology
2008;16(5):1146-1149
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death-1 ligand-1(PD-L1) is a recently identified member of the B7 family molecules and is shown to mediate the inhibition of immune responses. This study was purposed to enhance the weak immunological function of dendritic cells (DCs) derived from the patients with chronic myelocytic leukemia (CML) by blockade of the expression of PD-L1. Bone marrow mononuclear cells (BMMNCs) of CML patients were induced into DCs in the presence of cytokine cocktail of rhGM-CSF, rhIL-4 and TNF-alpha. The phenotypes of DCs were detected by flow cytometry, mixed lymphocyte reaction was analyzed by MTT assay and IFN-gamma, IL-2 and IL-10 in the cell culture supernatant were detected by ELISA. The results showed that the expression of PD-L1 on CML-DCs was upregulated with the maturation of CML-DCs. PD-L1-blockaded DCs could enhance T lymphocyte proliferation, increase the secretion of IL-2 and IFN-gamma, and inhibit the production of IL-10. Taken together, PD-L1-blockaded DCs originated from CML cells had more potent immunostimulatory capability. It is concluded that PD-L1 blockaded can enhance the function of CML-DCs. This approach presents new possibilities for achieving anti-tumor immunity by DC-based vaccination.
